Analysts Set ChemoCentryx Inc (CCXI) PT at $17.10

ChemoCentryx Inc (NASDAQ:CCXI) has received a consensus rating of “Buy” from the ten research firms that are presently covering the company, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $17.10.

Several equities analysts have weighed in on the stock. BidaskClub upgraded shares of ChemoCentryx from a “hold” rating to a “buy” rating in a report on Wednesday, November 28th. ValuEngine upgraded shares of ChemoCentryx from a “hold” rating to a “buy” rating in a report on Friday, August 10th. Canaccord Genuity raised their target price on shares of ChemoCentryx from $18.00 to $20.00 and gave the company a “buy” rating in a report on Monday, November 12th. Finally, HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of ChemoCentryx in a report on Monday, August 13th.

In other news, insider Thomas J. Schall sold 7,211 shares of ChemoCentryx stock in a transaction dated Wednesday, November 7th. The shares were sold at an average price of $12.00, for a total transaction of $86,532.00. Following the completion of the sale, the insider now directly owns 2,192,205 shares in the company, valued at $26,306,460. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Markus J. Cappel sold 30,237 shares of ChemoCentryx stock in a transaction dated Friday, October 26th. The stock was sold at an average price of $11.01, for a total transaction of $332,909.37. Following the sale, the insider now owns 54,063 shares of the company’s stock, valued at $595,233.63. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 7,380,940 shares of company stock valued at $86,264,863. Insiders own 14.50% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in CCXI. Bank of Montreal Can grew its holdings in ChemoCentryx by 861.4% in the second quarter. Bank of Montreal Can now owns 104,104 shares of the biopharmaceutical company’s stock valued at $1,371,000 after purchasing an additional 93,276 shares during the period. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in ChemoCentryx in the second quarter valued at approximately $315,000. Algert Global LLC purchased a new stake in ChemoCentryx in the second quarter valued at approximately $1,261,000. Alps Advisors Inc. grew its holdings in ChemoCentryx by 185.3% in the second quarter. Alps Advisors Inc. now owns 107,231 shares of the biopharmaceutical company’s stock valued at $1,412,000 after purchasing an additional 69,640 shares during the period. Finally, Sei Investments Co. grew its holdings in ChemoCentryx by 203.5% in the second quarter. Sei Investments Co. now owns 8,549 shares of the biopharmaceutical company’s stock valued at $113,000 after purchasing an additional 5,732 shares during the period. Hedge funds and other institutional investors own 53.83% of the company’s stock.

NASDAQ:CCXI traded down $0.17 during mid-day trading on Thursday, hitting $10.30. 11,176 shares of the company’s stock traded hands, compared to its average volume of 166,953. The company has a current ratio of 2.87, a quick ratio of 2.87 and a debt-to-equity ratio of 0.69. ChemoCentryx has a 1 year low of $5.42 and a 1 year high of $15.08. The company has a market capitalization of $507.78 million, a P/E ratio of 29.14 and a beta of 1.78.

ChemoCentryx (NASDAQ:CCXI) last posted its earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.03. ChemoCentryx had a net margin of 13.88% and a return on equity of 32.16%. The firm had revenue of $8.98 million during the quarter, compared to the consensus estimate of $11.55 million. On average, equities research analysts predict that ChemoCentryx will post -0.83 earnings per share for the current year.

ChemoCentryx Company Profile

ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV).

Read More: What is the NASDAQ?

Analyst Recommendations for ChemoCentryx (NASDAQ:CCXI)

Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit